ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced that it will present at the 14thAnnual Needham Healthcare Conference on Tuesday, April 14, 2015, at 9:20 a.m. Eastern Time in New York City.

A live webcast of ACADIA’s presentation will be accessible on the company’s website,, under the investors section and an archived recording will be available on the website throughApril 28, 2015(Original Source)

Shares of Acadia closed yesterday at $31.96 . ACAD has a 1-year high of $46.48 and a 1-year low of $15.64. The stock's 50-day moving average is $35.90 and it's 200-day moving average is $30.99.

On the ratings front, Acadia  has been the subject of a number of recent research reports. In a report issued on March 12, J.P. Morgan analyst Cory Kasimov reiterated a Buy rating on ACAD, with a price target of $40, which implies an upside of 25.2% from current levels. Separately, on the same day, Needham's Alan Carr reiterated a Buy rating on the stock and has a price target of $38.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Cory Kasimov and Alan Carr have a total average return of 8.3% and 42.0% respectively. Kasimov has a success rate of 46.3% and is ranked #788 out of 3568 analysts, while Carr has a success rate of 72.7% and is ranked #6.

The street is mostly Bullish on ACAD stock. Out of 5 analysts who cover the stock, 5 suggest a Buy rating . The 12-month average price target assigned to the stock is $42.80, which implies an upside of 33.9% from current levels.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.